Ann Pediatr Endocrinol Metab.  2021 Dec;26(4):259-265. 10.6065/apem.2040268.134.

Effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys with idiopathic central precocious puberty

• Cho AY
• Ko SY
• Lee JH
• Kim EY

• KMID: 2523832
• DOI: http://doi.org/10.6065/apem.2040268.134

Abstract

Purpose
There are few reports on the therapeutic effects of gonadotropin-releasing hormone agonists in boys with central precocious puberty, and studies reported in Korea are very rare. We aimed to assess the significance of clinical factors and the effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys diagnosed with central precocious puberty.
Methods
We retrospectively evaluated the medical records of 18 boys treated for idiopathic central precocious puberty between 2007 and 2018 at Chosun University Hospital. Gestational age, birth weight, and parental height were assessed at the initial visit. Chronological age, bone age, bone age/chronological age ratio, height and height standard deviation scores, predicted adult height, body mass index, and hormone levels were assessed during the treatment period.
Results
At the time of diagnosis, the chronological age was 9.9±0.6 years, the bone age was 11.6±1.0 years, and the bone age/chronological age ratio was 1.20±0.1. The bone age/chronological age ratio decreased significantly to 1.12±0.1 at the end of treatment (P<0.05). The luteinizing hormone/follicular stimulating hormone ratios were 3.4±1.2, 0.6±0.4, and 0.6±1.0 at the start of treatment, after 1 year of treatment, and at the end of treatment, respectively. After gonadotropin-releasing hormone agonist treatment, the final adult height reached 172.0±4.8 cm compared to the target height range of 171.0±4.0 cm.
Conclusion
In boys with central precocious puberty, gonadotropin-releasing hormone agonist treatment improved growth potential.

Keyword

Precocious puberty; Gonadotropin-releasing hormone; Boys

Figure

• 

  Fig. 1. Correlation between FAH and height, PAH, PAHa during treatment period. At start of treatment (A), 1 year after treatment (B), and end of treatment (C). FAH, final adult height; PAH, predicted adult height-calculated with average table of Baley-Pinneau (BP) method; PAHa, predicted adult height-calculated with advanced table of BP method.

Reference

References

1. Kim JH, Shin CH. Observed trends for an earlier onset of puberty: when is the need for treatment indicated. J Korean Med Assoc. 2009; 52:1189–200.

2. Mul D, Redriks AM, Van BS, Oostdijk W, Verloove-Vanhorick SP, Wit JM. Pubertal development in the Netherlands 1965-1997. Pediatr Res. 2001; 50:479–86.

3. Teilmann G, Pedersen CB, Jensen TK, Skakkebaek NE, Juul A. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics. 2005; 116:1323–8.

4. Carel JC, Léger J. Clinical practice. Precocious puberty. N Engl J Med. 2008; 358:2366–77.

5. Carel JC, Lahlou N, Roger M, Chaussi JL. Precocious puberty and statural growth. Hum Reprod Update. 2004; 10:135–47.

6. Rhie YJ, Lee KH. Overview and treatment of precocious puberty. J Korean Med Assoc. 2015; 58:1138–44.

7. John SF. Treatment and outcomes of precocious puberty. J Clin Endocrinol Metab. 2013; 98:2198–207.

8. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr. 1998; 157:363–7.

9. Lahlou N, Carel JC, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonist: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000; 13:723–37.

10. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Standford (CA): Standford University Press;1971.

11. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952; 40:423–41.

12. Kim JH, Yun SH, Hwang SS, Shim JO, Chae HW, Lee YJ, et al. The 2017 Korean national growth charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr. 2018; 61:135–49.

13. Lee JS, Kim JS, Yang AR, Cho SY, Jin DK. Etiology trends in male central precocious puberty. Ann Pediatr Endocrinol Metab. 2018; 23:75–80.

14. Alikasifoglu A, Vuralli D, Ozon A, Kandemir N. Changing etiological trends in male precocious puberty: Evaluation of 100 cases with central precocious puberty over the last decade. Horm Res Paediatr. 2015; 83:340–44.

15. Rhie YJ, Lee KH. Overview and treatment of precocious puberty. J Korean Med Assoc. 2015; 58:1138–44.

16. Mul D, Oostdijk W, Otten BJ, Rouwé C, Jansen M, Delemarre-van de Waal HA, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab. 2000; 13 Suppl 1:765–72.

17. De Sanctis V, Corrias A, Rizzo V, Bertelloni S, Urso L, Galluzzi F, et al. Etiology of central precocious puberty in males: the results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab. 2000; 13 Suppl 1:687–93.

18. Galluzzi F, Salti R, Bindi G, Paszuini E, La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr. 1998; 87:521–7.

19. Rizzo V, De Sanctis V, Corrias A, Fortini M, Galluzzi F, Bertelloni S, et al. Factors influencing final/near-final height in 12 boys with central precocious puberty treated with gonadotrophin-releasing hormone agonists. Italian Study Group of Physiopathology of Puberty. J Pediatr Endocrinol Metab. 2000; 13 Suppl 1:781–6.

20. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long term treatment with LHRH agonist: The National Institutes of Health experience. J Clin Endocrinol Metab. 2001; 86:4711–6.

21. Lazar L, Pertzelan A, Weintrob N, Phillip M, Kauli R. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab. 2001; 86:4127–32.

22. Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwe C, et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child. 1996; 75:292–7.

23. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999; 84:4583–90.

24. Lee HS, Yoon JS, Park KJ, Hwang JS. Increased final adult height by gonadotropin releasing hormone agonist in girls with idiopathic central precocious puberty. PLoS One. 2018; 13:e0201906.

25. Guaraldi F, Beccuti G, Gori D, Ghizzoni L. Management of endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol. 2016; 174:R79–87.

26. Cho AY, Ko SY, Lee JH, Kim EY. Relationship between final adult height and birth weight after gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2020; 25:24–30.

27. Tarım O. Height predictions by Bayley-Pinneau method may misguide pediatric endocrinologists. Turk J Pediatr. 2013; 55:485–92.

28. Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB Jr. Adult height in precocious puberty after longterm treatment with deslorelin. J Clin Endocrinol Metab. 1991; 73:1235–40.

29. Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab. 2005; 90:1371–6.